$ News

Jefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold Rating

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right

Is CARGO Therapeutics (NASDAQ:CRGX) In A Good Position To Deliver On Growth Plans?

CARGO Stock Surges 19% Pre-Market After Suspending Development, Cutting 90% of Workforce

Cargo shelves cell therapy research, lays off more staff

CARGO Therapeutics Provides Corporate Update

CARGO Therapeutics: A Gutted CAR T Player Trying To Find New Direction

After Plunging -69.58% in 4 Weeks, Here's Why the Trend Might Reverse for CARGO Therapeutics, Inc. (CRGX)

Here's Why CARGO Therapeutics, Inc. (CRGX) Could be Great Choice for a Bottom Fisher

CARGO Therapeutics, Inc. (CRGX) Upgraded to Buy: What Does It Mean for the Stock?

Top Midday Decliners

Cargo to drop lead CAR-T therapy, lay off staff after study setback

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options

CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025

CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround

Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics to Participate in Upcoming Investor Conferences

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity